RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

Completed · Phase 4

Conditions studied: Recurrent Genital Herpes (RGH)

In brief

This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.

Key facts

Study ID

NCT00219310

Run by

Novartis

Starts

2003-06-01

Expected to finish

2005-06-01

Last updated by the study team

2012-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Patients who are immunocompetent and who have had 4 or more episodes of Recurrent Genital Herpes (RGH) in the last 12 months.
• Patients with active HSV-2 or HSV-1 infection as confirmed by Polymerase Chain Reaction (PCR).
• Patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes

You may not qualify if…

• • Female patients who are pregnant or breast-feeding.
• Current, history or suspicion of liver disease or kidney disease.
• HIV infected (as confirmed by positive HIV serology).
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.